Bengaluru CRDMO: integrated drug discovery, development & manufacturing for global pharma/biotech clients.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 400 | 400 | 401 | 401 | 402 | 402 | 403 | 403 |
| Reserves | 1.8k | 2.4k | 2.9k | 3.2k | 3.9k | 4.3k | 4.3k | 4.4k |
| Borrowings | 773 | 893 | 1.0k | 815 | 555 | 578 | 582 | 458 |
| Other Liabilities | 1.2k | 1.2k | 1.2k | 1.4k | 1.3k | 1.5k | 1.2k | 1.8k |
| Total Liabilities | 4.2k | 4.9k | 5.6k | 5.8k | 6.2k | 6.8k | 6.5k | 7.1k |
| AssetsFixed Assets | 2.0k | 2.2k | 2.4k | 2.7k | 2.9k | 2.8k | 3.0k | 3.0k |
| CWIP | 234 | 237 | 346 | 177 | 838 | 1.3k | 989 | 1.0k |
| Investments | 776 | 702 | 1.0k | 918 | 548 | 647 | 547 | 741 |
| Other Assets | 1.1k | 1.7k | 1.8k | 2.1k | 1.9k | 2.1k | 2.0k | 2.3k |
| Total Assets | 4.2k | 4.9k | 5.6k | 5.8k | 6.2k | 6.8k | 6.5k | 7.1k |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (62.2×) and current (56.1×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -12% growth and a 56× exit, ₹441 only delivers your return if you pay ₹90. The price is currently baking in 18% growth.
EPS grows -12%/yr for 5 years, then fades to 6% over 2, exits at 56×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -12.0% | 6.92 |
| FY28 | -12.0% | 6.09 |
| FY29 | -12.0% | 5.36 |
| FY30 | -12.0% | 4.71 |
| FY31 | -12.0% | 4.15 |
| FY32 | -3.0% ·fade | 4.02 |
| FY33 | 6.0% ·fade | 4.26 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.